Cellectis S.A. · EURONEXT:ALCLS

Cellectis — Investor Presentation (January 2022)

27 slides from Cellectis's investor presentation, January 2022

  1. Slide 1: Corporate Presentation January 2022

    Commitment to a Cure Corporate Presentation January 2022 NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking” These forward-looking statements are made in light statements within the meaning of applicable of information currently available to us and are securities laws, including the Private Securities subject to numerous risks and unce

  3. Slide 3: Mission Statement

    Mission Statement CELLECTIS IS A CLINICAL-STAGE BIOTECH USING ITS PIONEERING GENE- EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES 3

  4. Slide 4: Key Highlights

    Key Highlights 3 ongoing clinical trials 140 patien ts dosed • 30+ patients dosed in Cellectis-sponsored trials + • In 5 trials sponsored by Cellectis’ licensed partners $201M GMP Meaningful facilities Milestones Expected Cash run operational Over the Next 12 way into since mid- Months 2024 2021manu

  5. Slide 5: Allogeneic CAR-T Cell Pipeline

    Allogeneic CAR-T Cell Pipeline Phase 1 Phase 1 Dose Dose Pivotal Upcoming Expected Product Disease Study Preclinical Escalation Expansion Phase2 Milestones DL3 with FCA Acute preconditioning UCART22 Lymphoblastic BALLI-01 Fully Owned Start dosing in-house Leukemia products Acute Myeloid DL2 and DL2i

  6. Slide 6: Diversified Partnerships with Industry Leaders

    Diversified Partnerships with Industry Leaders Exclusive worldwide license 2014 to CD19-directed allogeneic Up To $410M In Development & CAR T-cells CAR-T Sales Milestones U.S. Rights Sublicensed to CD19 + Low Double-Digit Royalties on 20151 Allogene by Servier Sales Exclusive worldwide CAR-T Up To

  7. Slide 7: Powerful and Comprehensive Gene Editing Platform

    Powerful and Comprehensive Gene Editing Platform Gene Knockout Gene Repair Gene Gene Insertion Replacement Nucleases Experts in Gene Editing: Self-owned  30+ years for Cellectis’ electroporation founders Base editors technology  22 years doing gene editing  10 years developing TALEN® Gene Knockou

  8. Slide 8: Why TALEN®?

    Why TALEN®? SAFE Avoids unintended genetic modifications EFFICIENT High rates of gene editing for Knock Outs and Knock PRECISE Ins Targets editing at the desired site (up to the base pair) Strong IP 8

  9. Slide 9: Why TALEN®? TALEN vs CRISPR

    Why TALEN®? TALEN® CRISPR PRECISION Every 7 base > Every 64 base pairs pairs ACTIVI TY KO, balanced KI > KO, unbalanced KI Euchromatin, GENOME OUTREACH heterochromatin >> Euchromatin only CUTTING FEATURES Centered > Distal RECOGNITION SITE 32 base pairs >> ~20 base pairs No chromothripsis Chromothri

  10. Slide 10: Our Focus in 2022

    Our Focus in 2022 Generate clinical data from our 3 ongoing trials To support determination of recommended phase 2 dose (RP2D) and lymphodepletion for: • UCART22 in r/r B-ALL patients • UCART123 in r/r AML patients • UCARTCS1 in r/r MM patients File IND & Initiate Phase 1 for • UCART20x22 in r/r NHL

  11. Slide 11: Cellectis Allogeneic CAR-T Cell Programs UCART Platform

    Cellectis Allogeneic CAR-T Cell Programs UCART Platform 11

  12. Slide 12: Allogeneic CAR-T cell Therapies are the Future

    Allogeneic CAR-T cell Therapies are the Future Scalable manufacturing “Off-the-shelf” availability Reduced cost: Immediately 1 batch = 100s ❶ ❷ available to patients doses Cancer Allogeneic Treatment UCART Decision Therapy Efficiency & robustness Market access Potency and Available to all consistenc

  13. Slide 13: Cellectis’ Clinical-Stage Candidate UCART Products

    Cellectis’ Clinical-Stage Candidate UCART Products TALEN® Powered Targeting CD123 CAR123 For AML TCRα KO Against GvHD Targeting CD22 CD52 KO CAR22 Resistance to For ALL alemtuzumab OR CS1 KO Targeting Self-lymphodepleting CD52 or CARCS1 CS1/SLAMF7 CS1 For MM 13

  14. Slide 14: UCART22 – BALLI-01 Trial Design

    UCART22 – BALLI-01 Trial Design Open Label Dose-escalation And Dose-expansion Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCART22 In Patients With Relapsed Or Refractory CD22 + B-cell Acute Lymphoblastic Leukemia Determine Dose Expansion Dose Escalation MTD and/or R

  15. Slide 15: UCART22 Administration Demonstrated a Tolerable Safety Profile

    UCART22 Administration Demonstrated a Tolerable Safety Profile PATIENT CHARACTERISTICS SAFETY: FCA Cohorts (N=6) (N=12) Median age: 30 (20-61) • 0 dose limiting toxicity WHO classification: • 0 ICANS (immune effector cell • B-ALL with recurrent genetic associated neurotoxicity) abnormalities: 7 (58%

  16. Slide 16: UCART22 Expansion Associated with Encouraging Anti-leukemic Activity

    UCART22 Expansion Associated with Encouraging Anti- leukemic Activity EFFICACY: FCA Cohorts (N=6)  Host lymphocytes on average remained suppressed  UCART22 Expansion was observed and was associated with anti-leukemic activity  2/6 patients achieved blast reductions to < 5% by day 28  1 pt in DL2

  17. Slide 17: UCARTCS1 – MELANI-01 Study Schema

    UCARTCS1 – MELANI-01 Study Schema Phase I, Open Label Dose-Escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1, Administered in Patients with Relapsed or Refractory Multiple Myeloma Screening LD Treatment Period Follow-up Total N= up to 18 UCARTCS1 pts D

  18. Slide 18: Preliminary Data Validate CS1 as a Target for CAR-T in Multiple Myeloma

    Preliminary Data Validate CS1 as a Target for CAR-T in Multiple Myeloma M protein D28: BM biopsy 4000 DL1 patient showed MRD by SerumIgG MRD-Neg VGPR 3000 FACS analysis M3: BM negative Serumfree lambdaLC 2000 for MM cells 1000 mg/dL 5 D90: IFE 4 +ve 3 2 1 0 Screening D0 D14 D28 M2(D49) M3(D77) D90

  19. Slide 19: UCART123 – AMELI-01 Trial Design

    UCART123 – AMELI-01 Trial Design Phase I, Open Label Dose-escalation And Dose-expansion Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCART123 In Patients With Relapsed or Refractory Acute Myeloid Leukemia Determine Dose Escalation MTD and/or Dose Expansion RP2D Up to

  20. Slide 20: UCART20x22 – A Dual Allogeneic CAR-T for B-cell Malignancies

    UCART20x22 – A Dual Allogeneic CAR-T cells for B-cell Why UCART20x22? Malignancies • Strong alternative to CD19 (highly competitive/crowded) • CD22 and CD20 are validated targets in B-cell malignancies • Dual targeting designed for better killing & to prevent target escape • Strong in vitro and in v

  21. Slide 21: UCART20x22 – Efficient Activity in Vivo Against Multiple Target Combinations

    UCART20x22 – Efficient Activity in Vivo Against Multiple Target Combinations Single mouse carrying Efficient in vivo clearance of subcutaneous lymphoma tumors tumors expressing one or two expressing different antigen antigens (CD20 and/or CD22) in a combinations dose dependent manner, starting at lo

  22. Slide 22: Cellectis’ UCART Platform Takeaways

    Cellectis’ UCART Platform Takeaways 170+ patients administered UCART derived from Cellectis’ technology 1. GvHD: TCRa KO results in safe, non-alloreactive UCART 2. Engraftment: CD52 KO + alemtuzumab provides a safe, effective & controllable therapeutic window 3. Persistence: Redosing feasible; encou

  23. Slide 23: Cellectis Organization

    CELLECTIS ORGANIZATION 23

  24. Slide 24: From UCART Discovery to Patients’ Bedside

    From UCART Discovery to Patients’ Bedside ALPHA Study Paris Raleigh, North New York, New Paris, France Carolina York HQ, PD/AD, Starting UCART – Clinical & Innovation, Clinical Materials Commercial Development 55,000 sq ft. 82,000 sq ft. facility 25,000 sq ft. facility facility  Cell therapy GMP 

  25. Slide 25: Cellectis 2022 Expected Milestones & Updates

    Cellectis 2022 Expected Milestones & Updates UCART22 UCART123 UCARTCS1 Enroll DL3 with FCA Enroll DL2 and DL2i Enroll DL1 with FC preconditioning and with FCA preconditioning start dosing with preconditioning products manufactured in- house GMP UCART20x22 PARTNERS FACILITIES File IND and initiate Re

  26. Slide 26: Key Takeaways – Why Cellectis?

    Key Takeaways – Why Cellectis? Innovative Allogeneic CAR-T Breaking Paradigms with Life-Saving Therapies End-to-end In-house Manufacturing Owning Manufacturing is Owning the Product Best-In-Class Gene Editing Platform Safe, Powerful & Comprehensive Strong Partnerships Diversified Indications Leading

  27. Slide 27: Thank You

    THANK YOU Reach us at: investors@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix 430 East 29th Street 2500 Sumner Boulevard Jarry 75013 Paris – 10016 New York, NY – 27616 Raleigh, NC – France USA USA

Cellectis — Investor Presentation (January 2022) on 6ix